ArticleBMC pulmonary medicine2026
Machine learning-based prediction of ventilator-associated pneumonia in ICU patients with type 2 diabetes.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVentilator-associated pneumonia (VAP) remains one of the most common and serious complications among mechanically ventilated patients in the ICU. Patients with type 2 diabetes mellitus (T2DM) are considered a vulnerable population for VAP because of impaired immune function and metabolic dysregulation. This study aimed to develop and validate machine learning (ML) models for the early prediction of VAP in mechanically ventilated ICU patients with T2DM.
methodsA total of 876 mechanically ventilated ICU patients with T2DM from the MIMIC-IV database were included and randomly divided into training and testing sets at a ratio of 7:3. Feature selection was performed using the Boruta algorithm, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and Spearman correlation analysis. The Synthetic Minority Over-sampling Technique (SMOTE) was applied to address class imbalance. Four ML models, including logistic regression (LR), random forest (RF), gradient boosting machine (GBM), and eXtreme Gradient Boosting (XGBoost), were developed. Model performance was comprehensively evaluated using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA), and multiple performance metrics, including recall, specificity, and F1-score. Shapley Additive Explanations (SHAP) were applied to interpret the optimal model, and a web-based risk calculator was further developed. In addition, sensitivity analyses were performed by retaining the Glasgow Coma Scale (GCS) score and using the original dataset without SMOTE to evaluate the robustness of the model.
resultsA total of 876 patients were included, of whom 73 developed VAP and 803 did not. XGBoost demonstrated the best predictive performance, with an area under the receiver operating characteristic curve (AUC) of 0.891 (95% CI 0.862-0.920), a recall of 0.832, a specificity of 0.877, and an F1-score of 0.851 in the testing set. Calibration curves showed good agreement between predicted and observed outcomes, and DCA indicated favorable potential clinical net benefit. SHAP analysis identified the seven most influential predictive features in the model, including Glucose_max, SOFA-Renal score, hypertension, Temp_min, Scr_max, WBC_min, and SOFA-CNS score.
conclusionFour ML models were developed and compared for the early prediction of VAP in mechanically ventilated ICU patients with T2DM, among which XGBoost demonstrated the best predictive performance. SHAP improved the interpretability of the model and identified the seven predictive features that contributed most to model predictions. Future prospective multicenter external validation studies are needed to further evaluate the model's generalizability and provide additional evidence for the early risk assessment of VAP in patients with T2DM.
Indexed as
Identifiers
43026537What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.